Icon
+91 94997 68112
Login Register

Picato - (0.015%: Gel, Topical)

Ingenol Mebutate Leo Pharma
0.015%: Gel, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
 None
Indicated for the topical treatment of actinic keratosis.
Yes
****(*******) & ******* *** *** ***** ** **** **** ** **** ’*** ****** (*** **, ****), ’*** ****** (*** *, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****) , *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** *** ’*** ****** (*** **, ****) *** **** ************ *********. ****** ***** **** ******* ***** * **** ** **** *** **** ******* ** ******* *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ********* **** ****(*******) & ******* ***** *** ***** ** ********* *** *** ***** *** ** ****** *** **** ** ****** ** ****** *.*. * ***** ***** *** ***** ****** ******, *** ***** ****** ******* ** *** ****.
Picato Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16
**** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* **** *** **** *** **** ***
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** *** *, **** ******* ********* ******** ****** ** ****
******* *** \ *** *** **, **** ******* ******** ****** ** ****
  1. *** **, **** : ******* ******** *** ****** ***** *** **** ** **** ’*** ****** (*** **, ****), ’*** ****** (*** *, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****) , *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** *** ’*** ****** (*** **, ****).
  2. *** *, **** : *** ****** ***** * **** ******* ******* ** ******** ***** ** ********.
  3. *** **, **** : ******* ******** *** ****** ***** *** **** ** **** ******* ’*** ****** (*** **, ****), ’*** ****** (*** *, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****) , *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** *** ’*** ****** (*** **, ****).
  4. *** **, **** : *** ****** ***** * **** ******* ******* ** ******** ***** ** ********.
  5. *** **, **** : ******* ******* *** *** ******* ** ***** **, ****.
  6. *** **, **** : ********** ********* **** ******* *** ******* *,***,***, *,***,***, *,***,***, *,***,***, *,***,***, *** *,***,***
  7. *** **, **** : ********** ********* **** ****(*******) *** *** *** ******* ** ****.
  8. *** **, **** : ********** ********* **** ******* *** *** *** ******* ** ****.

Picato - (0.05%; Gel, Topical)

Ingenol Mebutate Leo Pharma
0.05%; Gel, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
 None
Indicated for the topical treatment of actinic keratosis
Yes
Picato Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
**** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* **** *** **** *** **** ***
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** *** *, **** ******* ********* ******** ****** ** ****
******* *** \ *** *** **, **** ******* ******** ****** ** ****
  1. *** **, **** : ******* ******** *** ****** ***** *** **** ** **** ’*** ****** (*** **, ****), ’*** ****** (*** *, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****) , *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** *** ’*** ****** (*** **, ****), '***, '***, '***, '***
  2. *** **, **** : ******* ******** *** ****** ***** *** **** ** **** ******* ’*** ****** (*** **, ****), ’*** ****** (*** *, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****) , *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** ’*** ****** (*** **, ****), *** *** ’*** ****** (*** **, ****).
  3. *** *, **** : *** ****** ***** * **** ******* ******* ** ******** ***** ** ********.
  4. *** **, **** : *** ****** ***** * **** ******* ******* ** ******** ***** ** ********.
  5. *** **, **** : ********** ********* **** ******* *** ******* *,***,***, *,***,***, *,***,***, *,***,***, *,***,***, *** *,***,***
  6. *** **, **** : ********** ********* **** ****(*******) *** *** *** ******* ** ****.
  7. *** **, **** : ********** ********* **** ******* *** *** *** ******* ** ****.
  8. :
  9. :

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.